Case Report
Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature

Xubo Gong¹, Lijuan Yan², Xibin Xiao³, Qiusu Tang⁴, Xiaoying Zhao³

Departments of ¹Clinical Laboratory, ²Gastroenterology, ³Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; ⁴Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Received February 7, 2018; Accepted March 20, 2018; Epub June 1, 2018; Published June 15, 2018

Abstract: Therapy-related mixed phenotype acute leukemia (MPAL) following non-Hodgkin’s lymphoma (NHL) is extremely rare. We present here the case of an elderly man, diagnosed with diffuse large B-cell lymphoma (DLBCL) through a tonsil biopsy. After treatment with seven cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) like regimen, the patient developed to MPAL (B/myeloid) with del(7)(q22), t(6;9)(p23;q34), DEK/NUP214 fusion, as well as EZH2 and TET2 mutations. The patient was successively treated with chemotherapy and allogeneic hematopoietic stem cell transplantation. Until recently he is still alive more than 23 months without relapse.

Keywords: Diffuse large B-cell lymphoma, mixed phenotype acute leukemia, CHOP

Introduction
Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin’s lymphoma (NHL), which represents approximately 25-30% of all lymphomas and is the most common subtype throughout the world [1]. DLBCL is aggressive but potentially curable with multi-agent chemotherapy [1, 2]. The CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen has been the mainstay of therapy for several decades, and the addition of the anti-CD20 monoclonal antibody rituximab to CHOP has led to a marked improvement in survival [2-4].

However, several studies have reported an elevated risk of therapy-related malignancy overall following DLBCL or other NHL, such as solid and hematological tumors [3-8]. The risk of secondary acute leukemia after long-term treatment for NHL has been estimated at 1-1.5% per year from 2-10 years after the start of primary chemotherapy [8, 9]. Secondary acute myeloid leukemia (AML) following NHL was relatively less frequently reported than secondary acute lymphoid leukemia (ALL), and secondary mixed phenotype acute leukemia (MPAL) following NHL was much more rarely reported [9, 10].

In this paper, we describe a patient with DLBCL without chromosomal aberration at primary diagnosis. After treatment with a CHOP-like regimen, the patient developed a secondary mixed phenotype acute leukemia (MPAL) with chromosomal abnormalities and gene mutations. Our patient was successfully treated with chemotherapy and allogeneic hematopoietic stem cell (allo-HSC) transplantation.

Case report
In March 2012, a 56-year-old Chinese man was admitted with two weeks’ history of fever, tonsil pain, and enlargement of multiple cervical lymph nodes. Histological analysis of biopsied tonsil demonstrated DLBCL expressing CD20, CD79a, Bcl-2, Bcl-6, and PAX-5, but not CD3, CD30 (Ki-1), CD5, ALK, MPO, EBV, CD21 or CD10 (Figure 1). Laboratory data revealed that hemoglobin (Hb) was 112 g/L, red blood cell (RBC) count 3.54 × 10⁹/L, white blood cell
Therapy-related mixed phenotype acute leukemia

WBC count 6.5 × 10^9/L, and platelet (PLT) count 137 × 10^9/L. Both bone marrow (BM) smears and biopsies showed no abnormalities. Immunophenotyping and chromosomal analysis of BM aspirate was normal. In addition, computerized tomography (CT) of the chest, abdomen and pelvis did not reveal any changes suspicious for disease spread. Subsequently, chemotherapy according to the standard CHOP scheme was promptly administered leading to a rapid and progressive improvement. After treatment with six courses of CHOP regimen, the patient was asymptomatic.

In October 2014, he was hospitalized again for one month history of lower abdominal pain and lump. Abdominal CT scan showed intestinal obstruction. Laboratory data revealed that Hb was 108 g/L, WBC count 7.2 × 10^9/L, and PLT count 96 × 10^9/L. A biopsy sample obtained from the small intestine showed diffuse infiltration by DLBCL cells, which was confirmed by immunohistochemistry. In addition, histopathological examination showed DLBCL in 3 of 27 peri-intestinal lymph nodes. After surgical excision and elective lymph nodes dissection, the patient’s symptoms gradually improved. Subsequently, the patient received one cycle of standard CHOP chemotherapy plus rituximab.

Peripheral blood (PB) smears revealed 75% blasts, 12% neutrophils, 6% immature granulocyte, 6% lymphocyte, 1% basophilic granulocyte. The blasts were characterized by fine azurophilic granules with abundant cytoplasm, and irregular nuclei with 1-2 nucleoli.

BM smears were hypercellular with 85.5% blasts; the morphologic features were similar to those on PB smears. In addition, erythroid dysplasia was frequently observed. The blasts were 86% positive for myeloperoxidase staining, 92% for sudan black-B staining, and 82% for naphthol-AS-D chloracetate esterase staining, but they were negative for alpha-naphthyl butyrate esterase (Figure 2). BM trephine sections showed that blasts were positive for MPO, CD19 and CD22, but were negative for CD7 and CD3 (Figure 2).

Flow cytometric analysis of the BM aspirate showed that the blasts were positive for CD13 (94.46%), cMPO (67.61%), CD15 (45.36%), CD19 (64.92%), cCD79a (29.30), CyCD22 (31.3%), CD117 (48.61%), CD34 (98.62%) and HLA-DR (93.49%), but were negative for CD14, CD10, CD20, CD7, CD2, CD3, CD56 and CD61 (Figure 3).
Cytogenetic analysis of BM cells revealed 46, XY, del(7)(q22), t(6;9)(p23;q34) (Figure 4). Multiplex-nested reverse transcription PCR assay for DEK/NUP214 was positive, but for CBFB/MYH11, FLT3/ITD, TEL-AML1, MLL/AFX, MLL/AF4, MLL/AF6, MLL/AF9, MLL/AF10, MLL/ELL, MLL/AF1P, MLL/AF17, E2A/PBX1, BCR/ABL1, SIL/TAL1, AML1/ETO, MLL/ENL, NPM/ALK, PRKARIA/RARα, FIPIL1/RARα, NuP98/PMX1, NuP98/HOX13, NuP98/HOX11, NuP98/HOX13, NuP98/HOX11, NuP98/HOX10, ETV6/PDGFRβ, ETV6/RUNX1, ETV6-PDGFRα, FIPIL1/PDGFRα, NPM/RARα, PML/RARA, SET/CAN, DEK/CAN, TLS/ERG, PLZF/RARA, STAT5b/RARA, NuMA1/RARA, MLL/AF10, NPM/MLF1, TEL/ABL1, AML1/MDM2, E2A/HLF, dupMLL, HOX11, EVI1 and TEL/PDGFR were all negative. Fluorescence in situ hybridization analyses with probes for DEK/NUP214 was positive, but probes for CCND1/IGH, IGH/BCL-2, and PML/RARA were all negative. (Figure 5)

Genomic DNA for C-KIT, NPM1, FLT3-TKD, FLT3-ITD, EZH2, RUNX1, ASXL1, IDH1, IDH2, CBL, WT1, TET2, DNMT3A, PHF6, FBXW7, NOTCH1, ETV6, JAK-2V617F and TET3 were amplified, then the PCR products were sequenced. We observed EZH2 and TET2 mutations.

Based on the revised 2016 WHO criteria, the patient was diagnosed as therapy-related mixed phenotype acute leukemia (MPAL), B/myeloid, with del(7)(q22), t(6;9)(p23;q34), DEK/NUP214 fusion, as well as EZH2 and TET2 mutations.

After two course of induction chemotherapy with vincristine, daunorubicin, L-asparaginase, prednisone (VDLP) and Ara-c, the patient achieved complete remission. Then he received four courses of consolidation chemotherapy with DVP (daunorubicin, vincristine, and prednisone). After preconditioning with an improved busulfan and cyclophosphamide (Bu/Cy) regimen, the patient was successively treated with allogeneic hematopoietic stem cells (HSC) transplantation. At present he is alive more than 23 months without relapse.

**Discussion**

We present a unique case of secondary mixed phenotypic acute leukemia (MPAL) with del(7)(q22), t(6;9)(p23;q34), and DEK/NUP214 fusion after DLBCL. Immunophenotyping findings of our case show that the blasts co-expressed myeloid and B-lymphoid differentiation antigens. Morphologically, the blasts present with myeloid features, which can be easily mistaken for AML. We indicate that flow cytometry and immunohistochemistry should be the preferred method for establishing the diagnosis of MPAL.
Our patient has a history of DLBCL about three years. It is reported that NHL survivors have approximately twice the increased risk of secondary malignant neoplasm compared with the general population [7-9]. Young age, male sex, total body irradiation, alkylating agents and topoisomerase II inhibitors are the major risk factors associated with ANLL for NHL [6, 9], and the median time to development of therapy-related ANLL is 3 to 5 years [9, 10]. Our patient is an elderly man, who did not receive irradiation treatment; he received 7 courses of CHOP-like chemotherapy. Cyclophosphamide (alkylating agent) and (or) doxorubicin (topoisomerase II inhibitor), two important components of CHOP, may be highly associated with the development of MPAL for our patient.

In addition to chromosome abnormalities, EZH2 and TET2 mutations were also observed in our patient with secondary MPAL. But it is still uncertain whether the mutations have been present at the time of primary diagnosis for DLBCL. So we extracted genomic DNA from the patient’s paraffin-embedded bone marrow biopsies at the first diagnosis of DCBCL for comparison. After DNA amplification for EZH2 and TET2, the PCR products were sequenced, but no EZH2 or TET2 mutation was detected. Thus, besides del(7)(q22) and t(6;9)(p23;q34), the acquisition of EZH2 and TET2 mutations were
critical drivers of secondary MPAL to our patient.

MPAL is a rare disorder with an incidence of less than 2% of all acute leukemia. Therapy-related MPAL is even more rare; only four cases have been reported until recently [11-14]. Three cases were secondary after solid tumors (breast cancer, seminoma, and uterine cancer, respectively) [12-14], and the other case was secondary after NHL [11]. One common feature is that all four cases were treated with alkylating agent (cyclophosphamide or cisplatin). Many reports showed that MPAL had a high incidence of abnormal karyotype, especially positive Ph chromosome (Ph+) and t(1;19) abnormality [14-16]. To the best of our knowledge, MPAL with del(7)(q22), t(6;9)(p23;q34) and DEK/NUP214 fusion have not been reported in the literature.

Due to its heterogeneity, overlapping features with other types of ALL and AML, and lineage plasticity, MPAL has a poor prognosis particularly in adults, and secondary MPAL seems to have a worse clinical outcome compared with de novo cases [15, 16]. Currently, there are no special treatment guidelines for MPAL [16-18]. It is suggested that ALL-directed treatment seems more effective with a higher response rate and better outcome compared with AML or to an AML + ALL schedule, and tyrosine kinase inhibitors seems to be more effective to Ph+ MPAL [17-19]. Our patient achieved complete remission with chemotherapy and allogeneic HSC transplantation, and maintained a good quality of life without serious adverse events.

In summary, we report one unique case of therapy-related MPAL with del(7)(q22), t(6;9)(p23;q34), and DEK/NUP214 fusion, as well as EZH2 and TET2 mutations, following DLBCL with CHOP-like treatment. The clinical courses of the
present case suggests that allogeneic HSC transplantation is a safe and effective method for secondary MPAL.

Acknowledgements

This work was supported by National Natural Science Foundation of China (No. 81400107), Heath and Family Planning Commission of Zhejiang province (2015KYA110).

Disclosure of conflict of interest

None.

Address correspondence to: Xiaoying Zhao, Department of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, China. Tel: +86-571-87783672; Fax: +86-571-87074866; E-mail: zrxz@zju.edu.cn

References


